372 related articles for article (PubMed ID: 30898202)
1. Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays.
Ibrahim NE; McCarthy CP; Shrestha S; Gaggin HK; Mukai R; Szymonifka J; Apple FS; Burnett JC; Iyer S; Januzzi JL
J Am Coll Cardiol; 2019 Mar; 73(11):1273-1284. PubMed ID: 30898202
[TBL] [Abstract][Full Text] [Related]
2. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D
Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545
[TBL] [Abstract][Full Text] [Related]
3. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
Kobalava Z; Kotovskaya Y; Averkov O; Pavlikova E; Moiseev V; Albrecht D; Chandra P; Ayalasomayajula S; Prescott MF; Pal P; Langenickel TH; Jordaan P; Rajman I
Cardiovasc Ther; 2016 Aug; 34(4):191-8. PubMed ID: 26990595
[TBL] [Abstract][Full Text] [Related]
5. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
[TBL] [Abstract][Full Text] [Related]
6. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan.
Selvaraj S; Claggett BL; Böhm M; Anker SD; Vaduganathan M; Zannad F; Pieske B; Lam CSP; Anand IS; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2020 Apr; 75(14):1644-1656. PubMed ID: 32192799
[TBL] [Abstract][Full Text] [Related]
7. Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF).
Januzzi JL; Butler J; Fombu E; Maisel A; McCague K; Piña IL; Prescott MF; Riebman JB; Solomon S
Am Heart J; 2018 May; 199():130-136. PubMed ID: 29754651
[TBL] [Abstract][Full Text] [Related]
8. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
9. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.
Vasquez N; Carter S; Grodin JL
Curr Heart Fail Rep; 2020 Jun; 17(3):67-76. PubMed ID: 32394149
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
[TBL] [Abstract][Full Text] [Related]
13. Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
Murphy SP; Prescott MF; Camacho A; Iyer SR; Maisel AS; Felker GM; Butler J; Piña IL; Ibrahim NE; Abbas C; Burnett JC; Solomon SD; Januzzi JL
JACC Heart Fail; 2021 Feb; 9(2):127-136. PubMed ID: 33189632
[TBL] [Abstract][Full Text] [Related]
14. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL
JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
Ambrosy AP; Braunwald E; Morrow DA; DeVore AD; McCague K; Meng X; Duffy CI; Rocha R; Velazquez EJ;
J Am Coll Cardiol; 2020 Sep; 76(9):1034-1048. PubMed ID: 32854838
[TBL] [Abstract][Full Text] [Related]
16. BNP and NT-proBNP Interpretation in the Neprilysin Inhibitor Era.
Sbolli M; deFilippi C
Curr Cardiol Rep; 2020 Sep; 22(11):150. PubMed ID: 32951154
[TBL] [Abstract][Full Text] [Related]
17. Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension.
Engeli S; Stinkens R; Heise T; May M; Goossens GH; Blaak EE; Havekes B; Jax T; Albrecht D; Pal P; Tegtbur U; Haufe S; Langenickel TH; Jordan J
Hypertension; 2018 Jan; 71(1):70-77. PubMed ID: 29180454
[TBL] [Abstract][Full Text] [Related]
18. Effects of sacubitril/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction ≤35.
Pugliese NR; Fabiani I; Zywicki V; Mazzola M; D'Agostino A; Galeotti GG; Dini FL
Curr Med Res Opin; 2019 May; 35(sup3):13-18. PubMed ID: 30895809
[TBL] [Abstract][Full Text] [Related]
19. Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men.
Thonsgaard S; Prickett TCR; Hansen LH; Wewer Albrechtsen NJ; Andersen UØ; Terzic D; Plomgaard P; Gustafsson F; Goetze JP; Mark PD
Clin Chem; 2022 May; 68(5):713-720. PubMed ID: 35175317
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
